Allergen immunotherapy for birch pollen-allergic patients: recent advances.

about

Unbiased Quantitative Proteomics Reveals a Crucial Role of the Allergen Context for the Activation of Human Dendritic Cells.Characterization of epitope specificities of reference antibodies used for the quantification of the birch pollen allergen Bet v 1.

P2860

Q47124635-59E17558-802A-4377-9BCC-010AD999A040 Q48240468-AF1CF553-DB20-4F68-A387-D2FF992C845C

P2860

Allergen immunotherapy for birch pollen-allergic patients: recent advances.

Item

http://www.wikidata.org/entity/Q38824177

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Allergen immunotherapy for birch pollen-allergic patients: recent advances.

@en

type

Item

label

Allergen immunotherapy for birch pollen-allergic patients: recent advances.

@en

prefLabel

Allergen immunotherapy for birch pollen-allergic patients: recent advances.

@en

P1476

Allergen immunotherapy for birch pollen-allergic patients: recent advances

@en

P2093

Laurent Mascarell

http://www.w3.org/2001/XMLSchema#string

Philippe Moingeon

http://www.w3.org/2001/XMLSchema#string

Sabi Airouche

http://www.w3.org/2001/XMLSchema#string

Véronique Baron-Bodo

http://www.w3.org/2001/XMLSchema#string

Véronique Bordas-Le Floch

http://www.w3.org/2001/XMLSchema#string

P2860

Needle free injection technology: A complete insight

Crystallographically Mapped Ligand Binding Differs in High and Low IgE Binding Isoforms of Birch Pollen Allergen Bet v 1

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients

X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy

Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy

Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy.

Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1.

Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization.

Specific immunotherapy.

P304

555-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2217/IMT-2015-0027

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel Nony

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27140409

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

pollen

Allergen immunotherapy for birch pollen-allergic patients: recent advances.

about

P2860

P2860

Allergen immunotherapy for birch pollen-allergic patients: recent advances.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921